Amidst a fluctuating Australian market where the ASX200 has seen a slight decline and sectors like IT have struggled significantly, small-cap stocks continue to present unique opportunities. Particularly, certain undervalued small caps are drawing attention with insider actions suggesting potential unrecognized value in this turbulent economic landscape. In such conditions, discerning investors might look for stocks that not only show promising fundamentals but also exhibit positive insider engagements, hinting at confidence from those who know the company best. Top 10 Undervalued Small Caps With Insider Buying In Australia Name PE PS Discount to Fair Value Value Rating Corporate Travel Management 17.5x 2.7x 47.31% ★★★★★★ Nick Scali 13.7x 2.5x 45.54% ★★★★★★ Healius NA 0.6x 43.37% ★★★★★☆ Codan 28.6x 4.2x 27.32% ★★★★☆☆ Dicker Data 20.8x 0.8x 3.61% ★★★★☆☆ Eagers Automotive 9.6x 0.3x 33.24% ★★★★☆☆ Tabcorp Holdings NA 0.7x 19.38% ★★★★☆☆ RAM Essential Services Property Fund NA 5.8x 40.26% ★★★★☆☆ Smartgroup 17.5x 4.3x 49.61% ★★★☆☆☆ Coventry Group 295.6x 0.4x -21.34% ★★★☆☆☆ Click here to see the full list of 27 stocks from our Undervalued ASX Small Caps With Insider Buying screener. Let's review some notable picks from our screened stocks. Codan Simply Wall St Value Rating: ★★★★☆☆ Overview: Codan is a diversified technology company specializing in communications and metal detection, with a market capitalization of approximately A$1.37 billion. Operations: Communications and Metal Detection are the primary revenue contributors, generating A$291.50 million and A$212.20 million respectively. The company's gross profit margin has shown a trend of fluctuation, with recent figures around 54.42% for the latest reported period. PE: 28.6x Codan, a notable player in the Australian market, recently saw insider confidence demonstrated through share purchases, signaling strong belief in the company's prospects. With earnings expected to grow by 16% annually, this reflects positively on its financial trajectory. Despite relying solely on external borrowing—a riskier funding method—these strategic moves suggest a robust foundation for future growth. This blend of insider activity and solid growth forecasts paints Codan as an appealing prospect for those eyeing potential in lesser-known entities. Dive into the specifics of Codan here with our thorough valuation report. Learn about Codan's historical performance. ASX:CDA Share price vs Value as at Jul 2024 Lifestyle Communities Simply Wall St Value Rating: ★★★☆☆☆ Overview: Lifestyle Communities is a company engaged in property development and management, with a market capitalization of approximately A$1.5 billion. Operations: In recent financial data, the company reported a gross profit margin of 21.02% and a net income margin of 32.38%. This performance is derived from its primary operation in property development and management, which generated A$239.11 million in revenue. PE: 19.6x Lifestyle Communities, a notable player in the Australian market, recently showcased at the Macquarie Australia Conference. With earnings expected to climb by 22% annually, this reflects strong future prospects. Despite relying on higher-risk funding with no customer deposits, they maintain a good financial stance with significant non-cash earnings. Notably, insiders have recently demonstrated their confidence through share purchases, underscoring a belief in the company’s potential growth and current market positioning as undervalued. Get an in-depth perspective on Lifestyle Communities' performance by reading our valuation report here. Explore historical data to track Lifestyle Communities' performance over time in our Past section. ASX:LIC Ownership Breakdown as at Jul 2024 Neuren Pharmaceuticals Simply Wall St Value Rating: ★★★★★★ Overview: Neuren Pharmaceuticals is a company focused on the development of pharmaceutical products, with a market capitalization of approximately A$231.94 million. Operations: Pharmaceutical Products generated A$231.94 million in revenue, with a gross profit margin of 88.47%. The company's operating expenses were A$5.95 million. PE: 16.4x Neuren Pharmaceuticals, a lesser-known entity in the Australian market, recently showcased promising Phase 2 clinical trial results for NNZ-2591, targeting Pitt Hopkins syndrome—a condition with no approved treatments. This development could significantly enhance its market position. With revenue projected to increase by over 10% annually, and backed by insider confidence demonstrated through recent share purchases, Neuren's strategic moves suggest a potential upward trajectory in its valuation amidst small-cap peers. Delve into the full analysis valuation report here for a deeper understanding of Neuren Pharmaceuticals. Evaluate Neuren Pharmaceuticals' historical performance by accessing our past performance report. ASX:NEU Share price vs Value as at Jul 2024 Make It Happen Take a closer look at our Undervalued ASX Small Caps With Insider Buying list of 27 companies by clicking here. Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments. Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world. Searching for a Fresh Perspective? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include ASX:CDAASX:LIC and ASX:NEU. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]
Top Undervalued Small Caps With Insider Actions In Australia July 2024
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...